详情页 - 昆明医科大学第一附属医院知识库

当前位置：首页 > 详情页

Suppression of mir-150-5p attenuates the anti-inflammatory effect of glucocorticoids in mice with ulcerative colitis

34| 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Department of Intensive Care Unit, The First Affiliated Hospital of Kunming Medical University, Kunming, China [2]Department of Internal Medicine, Kunming Meizhao Physical Examination Center, Kunming, China

出处：

DOI：

ISSN：

关键词： Glucocorticoid resistance Ulcerative colitis Mir-150–5p Dexamethasone Inflammatory bowel disease

摘要：

Glucocorticoids have been widely used in the treatment of ulcerative colitis, but not all patients benefit from this therapy due to hormone resistance. Mir-150-5p has been reported to enhance the efficacy of glucocorticoids, and low serum mir-150-5p expression has been linked to glucocorticoid resistance in ulcerative colitis patients. The aim of this study was to elucidate the mechanisms of mir-150-5p regulation on glucocorticoid resistance. An ulcerative colitis mouse model was used to evaluate changes in ulcerative colitis symptoms, inflammatory factors, and glucocorticoid resistance-related gene expression. The results showed that mir-150-5p suppression with antagomirs did not significantly interfere with or enhance the induction of ulcerative colitis symptoms by dextran sulfate sodium, but it did attenuate the inflammation inhibitory effect of dexamethasone by abnormally regulating the expression of IL-17a, IL-10, IL-2 and IL-6 levels and myeloperoxidase activity. Mir-150-5p inhibition also induced a glucocorticoid-resistant gene expression profile in colon tissues of ulcerative colitis mice, with upregulation of p-ERK, p-JNK, and HSP90 and downregulation of p-GRa, FKBP4, and HDAC2 expression. Our results indicate that mir-150-5p suppression attenuates the anti-inflammatory effect of glucocorticoids and may function as a driver element in ulcerative colitis glucocorticoid resistance. AVAILABILITY OF DATA AND MATERIALS: All data and figures analyzed in this study are available from the corresponding author by request.Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2024]版：

无

最新[2023]版：

大类 | 3 区医学

小类 | 3 区生化与分子生物学 3 区免疫学

JCR分区：

出版当年[2023]版：

Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY Q3 IMMUNOLOGY

最新[2023]版：

Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY Q3 IMMUNOLOGY

影响因子： 3.2 最新[2023版] 3.6 最新五年平均 3.2 出版当年[2023版] 3.6 出版当年五年平均 3.6 出版前一年[2022版]

第一作者：

第一作者机构： [1]Department of Intensive Care Unit, The First Affiliated Hospital of Kunming Medical University, Kunming, China

共同第一作者：

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3) [2]The hospitalization burden of inflammatory bowel disease in a southwestern highland region of China: a territory-wide study from 2015 to 2020 [3]Differential expression of serum microRNAs in glucocorticoid-resistant patients with ulcerative colitis. [4]炎症性肠病的诱导缓解策略 [5]Differential expression of serum microRNAs in glucocorticoid-resistant patients with ulcerative colitis [6]昆明市10家医院炎症性肠病患者临床资料分析 [7]Natural course of ulcerative colitis in China: Differences from the West? [8]Editorial: Microbiome in IBD: From Composition to Therapy [9]Editorial: Microbiome in IBD: From Composition to Therapy, Volume II [10]Non-drug treatment of inflammatory bowel disease(Open Access)